(Press Enter)
Patients are at the center of everything we do. They inspire us. They are the reason we come to work each day. Our R&D organization is composed of industry-leading researchers and drug developers who have a passion for science, a curiosity for discovery and a commitment to translating these advances into medicines that make a difference for patients. Supported by robust capabilities, unmatched collective experience and a strong, global presence, we are advancing science through internally discovered medicines as well as external partnerships. Partnership and collaboration are essential to our strategy. We anchor ourselves within vibrant healthcare innovation ecosystems, where academic research centers and biotech and biopharma companies all contribute to continued scientific advancement. We bring therapies to market with a strong sense of urgency and the utmost precision and care.
As a leading biopharma company, partnering is a key priority for us and plays a critical role in our strategy. We seek to combine external innovative science and technologies with our internal capabilities and expertise to transform patients’ lives through science. Partnerships and collaborations are essential to evolving our portfolio and driving our long-term sustainability.
Partnering has been an integral part of our evolution to become a leading biopharma company – it’s part of our DNA. As critical drivers of our strategy, external innovation and partnering have brought significant commercial success and pipeline growth. Our long and proven track record of partnering exhibits speed, transparency, flexibility, creativity and above all, a focus on innovative science and delivering transformational medicines to patients. This includes exciting collaborations with DragonFly, Insitro, Janssen, Obsidian Therapeutics, Prothera, Pfizer, and Voluntis, as well as the acquisition of Forbius to expand our TGF-beta program for oncology and fibrosis. See our Forward-Looking Information for more.
